Home

Date register of trial

Trials for date register in the RPCEC

Date of Registration Public title Sponsorsort icon State
14/08/2014 Study of intensive pediatric pharmacovigilance of nimotuzumab for the treatment of malignant glioma tumors. CIMAB Registered
26/08/2013 ior ®EPOCIM as a cardioprotective agent in the surgery of rheumatic valvular disease. CIMAB Registered outdated
11/09/2014 NeuroEPO-Stroke. Phase I-II CIMAB Registered
02/11/2014 NeuroEPO – Type 2 Spinocerebellar Ataxia Phase I-II CIMAB Registered
2012-07-20 T1h in severe psoriasis-expanded access program (PUCE) CIM Registered
2010-12-03 1E10 anti-idiotype vaccine, metastatic colon, phase II. CIM Registered
2010-12-24 Toxicological evaluation of the humanized Anti-CD6 MAb T1h in Rheumatoid Arthritis Patients CIM Registered
2010-12-27 1E10 anti-idiotype vaccine, metastatic breast cancer, phase II CIM Registered
2010-12-28 Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patients CIM Registered
2010-12-28 Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patients CIM Registered
2010-12-28 h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II. CIM Registered
2010-12-28 hR3 MaB and radiotherapy in highly malignant astrocytic tumors, phase III. CIM Registered
2010-12-29 h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin. CIM Registered
2010-12-29 NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II. CIM Registered
2010-12-29 Patients with non small cells lung cancer (NSCLC) and brain metastasis. CIM Registered
2010-12-29 hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma. CIM Registered
2010-12-29 hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment. CIM Registered
2010-12-29 14F7 MAb marked with Tc99 Phase II in breast tumors. CIM Registered
2008-12-27 99mTc-marked 14F7 MaB in metastatic breast, phase II CIM Registered
2010-12-27 Evaluation of Safety and Efficacy of T1h (anti-CD6) as Monotherapy and in Combination with Methotrexate in Patientes with Rheumatoid Arthritis CIM Registered